Table 1

Baseline characteristics of subjects with or without fracture during follow-up by ITT analysis

Fracture during follow-up
CharacteristicYes (n = 481)No (n = 16,011)P value
Demographic characteristics
 Age, median (IQR), years 67 (13)65 (11)<0.0001
 Female sex, n (%)236 (49.1)5,219 (32.6)<0.0001
 Race
  Caucasian, n (%)407 (84.6)12,000 (74.9)<0.0001
  All others, n (%)74 (15.4)4,011 (25.1)
 Hispanic/Latino ethnicity, n (%)74 (15.4)3,467 (21.7)0.0007
 Weight, median (SD), kg85.2 (27.2)86.0 (25.2)0.8280
 BMI, median (SD), kg/m230.86 (7.84)30.45 (7.20)0.1572
 Diabetes duration, median (IQR), years12.66 (13.77)10.29 (11.36)<0.0001
 Current smoker, n (%)60 (12.5)2,159 (13.5)0.5873
 Hypertension, n (%)408 (84.8)13,084 (81.7)0.0928
 Dyslipidemia, n (%)368 (76.5)11,371 (71.0)0.0091
 Prior myocardial infarction, n (%)150 (31.2)6,087 (38.0)0.0022
 Prior heart failure, n (%)78 (16.2)2,027 (12.7)0.0262
 Prior coronary revascularization, n (%)219 (45.5)6,904 (43.1)0.293
Baseline measurements
 eGFR, median (SD), mL/min66.3 (31.3)71.8 (29.3)<0.0001
 Albumin-to-creatinine ratio, median (SD), mg/mmol2.1 (9.7)1.8 (6.9)0.5697
 HbA1c, median (SD), % 7.5 (1.6)7.6 (1.8)0.1236
 Fasting serum glucose, median (SD), mg/dL142 (60)145 (64)0.0652
Baseline CV medications, n (%)
 Aspirin349 (72.6)12,055 (75.3)0.1801
 Statins392 (81.5)12,525 (78.2)0.0919
 β-Blockers284 (59.0)9,878 (61.7)0.2534
 Diuretics232 (48.2)6,833 (42.7)0.0170
 ACE inhibitors252 (52.4)8,688 (54.3)0.4299
Baseline antihyperglycemic medications, n (%)
 Metformin310 (64.4)11,113 (69.4)0.0211
 Sulfonylurea179 (37.2)6,407 (40.0)0.2197
 TZD39 (8.1)931 (5.8)0.0389
 Insulin239 (49.7)6,548 (40.9)0.0001
  • Categorical variables were compared using the χ2 or Fisher exact test and continuous variables with the t test. P < 0.05 was considered to be statistically significant. P values were not adjusted for multiple testing.

  • IQR, interquartile range.